Eisai Facility FDA-483 Out

FDA has just released the form FDA-483 issued following a 10/23-10/27/2023 inspection at the Eisai drug manufacturing facility in Gifu, Japan. The two observations were:

  • failure to maintain in writing and fully follow the responsibilities and procedures applicable to the quality control unit; and
  • failure to store drug products under appropriate conditions of humidity so that their identity, strength, quality, and purity are not affected.

Read more